Biosergen AB (publ) (STO:BIOSGN)

Market Cap	3.22M -96.9%
Revenue (ttm)	n/a
Net Income	-32.32M
EPS	-13.77
Shares Out	2.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376,100
Open	1.350
Previous Close	1.370
Day's Range	1.320 - 1.890
52-Week Range	0.700 - 55.200
Beta	-0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About Biosergen AB

Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BIOSGN

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error